$OPGN catalyst: FDA decision Acuitas AMR Gene Panel
Hyping on twitter: Added New position 
OPGN primarily for the top catalyst FDA decision Acuitas AMR Gene Panel. In addition, pipeline includes Broad pathogen and Antimicrobial Resistance Marker coverage. 53 M market cap. Eyeing $3.3 breakout target towards $4 plus. Should spike on FDA decision.
twitter.com/Pharmdca/status/1358837925039935490
OPGN primarily for the top catalyst FDA decision Acuitas AMR Gene Panel. In addition, pipeline includes Broad pathogen and Antimicrobial Resistance Marker coverage. 53 M market cap. Eyeing $3.3 breakout target towards $4 plus. Should spike on FDA decision.twitter.com/Pharmdca/status/1358837925039935490
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。